Opdivo

PsiOxus Therapeutics-Bristol Myers Expand Immuno-Oncology Collaboration

Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study

Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study

Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Merck, Bristol Myers Shares Move On Alleged FDA Alert On Keytruda

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Opdivo Recent News

Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight

Bristol-Myers Stock May Have Exhausted Its Upside For Now

Mirati Therapeutics Sitravatinib Data, Explained

The Most Notable Abstracts Released Ahead Of ASCO 2017

Sympathy Moves, Explained: Unsympathetic Earnings Season Continues As Nvidia, Advanced Micro Devices Diverge

Carl Icahn's Track Record In Big Pharma

Merck's Keytruda Gains Momentum At The Expense Of Bristol-Myers

Which Pharma Players Dominate The Lung Cancer Space?

Here's What Merck's Keytruda News Means For Bristol-Myers

The ESMO Conference Proves Its Ability To Move Stocks

This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year

Bristol-Myers Opdivo Vs. Merck's Keytruda In Front Line Lung Treatment

SunTrust Cuts Target On Bristol-Myers As Opdivo Estimates Revised Lower

Seattle Genetics No Longer On Goldman Sachs' Sell List

Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain

Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict

Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts

Friday Market Wrap: Stock Market Jumps On Employment Numbers

BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations

JPMorgan's Take On Big Pharma's New ASCO Abstracts

The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers